TNYA
Tenaya Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.67
−0.27%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.68
From 52W high−68.08%
Volume2.63M
Market cap$150.32M
P/E (TTM)—
P/S (TTM)112.6x
Div yield—
Key dataSep 18, 2026
Open
$0.68
From 52W high
−68.08%
Volume
2.63M
Market cap
$150.32M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.8x
P/E (TTM)
—
RSI (14)
47.0
MomentumView details →
1D Return
−0.27%
YTD Return
−4.46%
SummaryUpdated Jun 1, 2026
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) is a biotechnology company founded in 2016 and headquartered in South San Francisco, California. The company went public in July 2021 and focuses on developing innovative therapies for heart disease through three distinct technological platforms: cellular regeneration, gene therapy, and precision medicine. Since its inception, Tenaya has been dedicated to addressing the significant unmet medical needs in cardiovascular medicine, particularly targeting genetic forms of heart disease that currently have limited treatment options.
Similar companies
Latest newsMore news →
The U.S. FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Tenaya Therapeutics' TN-401 for the treatment of PKP2-associated arrhythmogenic right ventricular cardiomyopathy.6d agoTenaya Therapeutics granted stock options to its newly appointed CFO Eric Hyllengren and two new non-executive employees upon their employment commencement.68d ago